Brief: Neuren Pharmaceuticals Says Daybue Q1 2024 Net Sales $75.9 Million
09/05/2024 01:15
May 9 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* DAYBUE Q1 2024 NET SALES US$75.9 MILLION
* DAYBUE FULL-YEAR GUIDANCE OF US$370-420 MILLION
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union